Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Jacobs, Julie ^a,b   Smits, Evelien ^a   Lardon, Filip ^a   Pauwels, Patrick ^a,b   Deschoolmeester, Vanessa ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD134 ANTIGEN; CD137 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD70 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; KIDNEY INJURY MOLECULE 1; LYMPHOCYTE ACTIVATION GENE 3; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTITUMOR IMMUNITY; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DISEASE ASSOCIATION; FIBROBLAST; HUMAN; IMMUNE RESPONSE; IMMUNOEDITING; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NEOPLASM; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; COLORECTAL NEOPLASMS; GENETICS; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; PATHOPHYSIOLOGY; PROCEDURES;

ADAPTIVE IMMUNITY; COLORECTAL NEOPLASMS; HUMANS; IMMUNE SYSTEM PHENOMENA; IMMUNITY, INNATE; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY;

EID: 84947483881     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/158038     Document Type: Review

References (106)

1. J. M. Young, M. Jorgensen, andM. Solomon, "Optimal delivery of colorectal cancer follow-up care: improving patient outcomes," Patient Related Outcome Measures, vol. 6, pp. 127-138, 2015.
2. M. Gonzalez-Pons and M. Cruz-Correa, "Colorectal cancer biomarkers:where arewe now?" BioMed Research International, vol. 2015, Article ID149014, 14 pages, 2015.
3. V. Deschoolmeester, E. Smits, M. Peeters, and J. B. Vermorken, "Status of active specific immunotherapy for stage II, stage III, and resected stage IV colon cancer," Current Colorectal Cancer Reports, vol. 9, no. 4, pp. 380-390, 2013.
4. P. Kocin,M. Sedivcov, J. Drgc et al., "Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRASmutational status and disease recurrence," Human Immunology, vol. 72, no. 11, pp. 1022-1028, 2011.
5. V. Deschoolmeester, M. Baay, P. Specenier, F. Lardon, and J. B. Vermorken, "A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy," Oncologist, vol. 15, no. 7, pp. 699-731, 2010.
6. J. L. Markman and S. L. Shiao, "Impact of the immune system and immunotherapy in colorectal cancer," Journal of Gastrointestinal Oncology, vol. 6, no. 2, pp. 208-223, 2015.
7. T.-T. Chen, "Milestone survival: a potential intermediate endpoint for immune checkpoint inhibitors," Journal of the National Cancer Institute, vol. 107, no. 9,Article ID djv156, 2015.
8. S. Pernot, M. Terme, T. Voron et al., "Colorectal cancer and immunity: what we know and perspectives," World Journal of Gastroenterology, vol. 20, no. 14, pp. 3738-3750, 2014.
9. V. Shankaran, H. Ikeda, A. T. Bruce et al., "IFN, and lymphocytes prevent primary tumour development and shape tumour immunogenicity," Nature, vol. 410, no. 6832, pp. 1107-1111, 2001.
10. M. Amin and A. C. Lockhart, "The potential role of immunotherapy to treat colorectal cancer," Expert Opinion on Investigational Drugs, vol. 24, no. 3, pp. 329-344, 2015.
11. M. Liljefors, B. Nilsson, A.-L. Hjelm Skog, P. Ragnhammar, H. Mellstedt, and J.-E. Frödin, "Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A," International Journal of Cancer, vol. 105, no. 5, pp. 717-723, 2003.
12. S. Coca, J. Perez-Piqueras, D. Martinez et al., "The prognostic significance of intratumoral natural killer cells in patients with colerectal carcinoma," Cancer, vol. 79, no. 12, pp. 2320-2328, 1997.
13. S. M. Keon, M. S. Ruiz, S. Gazzaniga, and R. Wainstok, "Dendritic cell-based vaccination in cancer: therapeutic implications emerging frommurinemodels," Frontiers in Immunology, vol. 6, article 243, 2015.
14. D. Nagorsen, S. Voigt, E. Berg, H. Stein, E. Thiel, and C. Loddenkemper, "Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival," Journal of Translational Medicine, vol. 5, article 62, 2007.
15. S. Edin, M. L. Wikberg, P.-A. Oldenborg, and R. Palmqvist, "Macrophages: good guys in colorectal cancer," OncoImmunology, vol. 2, no. 2,Article ID e23038, 2013.
16. K. Ohnishi, Y. Komohara, Y. Saito et al., "CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma," Cancer Science, vol. 104, no. 9, pp. 1237-1244, 2013.
17. M. Erreni, A. Mantovani, and P. Allavena, "Tumor-associated macrophages (TAM) and inflammation in colorectal cancer," Cancer Microenvironment, vol. 4, no. 2, pp. 141-154, 2011.
18. J. Bystrom, T. E. Taher, M. S. Muhyaddin et al., "Harnessing the therapeutic potential of Th17 cells," Mediators of Inflammation, vol. 2015, Article ID205156, 11 pages, 2015.
19. S. R. Bailey, M. H. Nelson, R.A. Himes, Z. Li, S. Mehrotra, and C. M. Paulos, "Th17 cells in cancer: the ultimate identity crisis," Frontiers in Immunology, vol. 5, article 276, 2014.
20. V. Deschoolmeester, M. Baay, E. Van Marck et al., "Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients," BMC Immunology, vol. 11, article 19, 2010.
21. D. M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy," Nature Reviews Cancer, vol. 12, no. 4, pp. 252-264, 2012.
22. J. R. Brahmer and D. M. Pardoll, "Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer," Cancer Immunology Research, vol. 1, no. 2, pp. 85-91, 2013.
23. J. R. Brahmer, C. G. Drake, I. Wollner et al., "Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates," Journal of Clinical Oncology, vol. 28, no. 19, pp. 3167-3175, 2010.
24. R. J. Greenwald,G. J. Freeman, and A.H. Sharpe, "The B7 family revisited," Annual Review of Immunology, vol. 23, pp. 515-548, 2005.
25. E. N. Rozali, S. V. Hato, B. W. Robinson, R. A. Lake, and W. J. Lesterhuis, "Programmed death ligand 2 in cancer-induced immune suppression," Clinical andDevelopmental Immunology, vol. 2012, Article ID656340, 8 pages, 2012.
26. X. Wu, H. Zhang, Q. Xing et al., "PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients," British Journal of Cancer, vol. 111, no. 7, pp. 1391-1399, 2014.
27. J. Ge, L. Zhu, J. Zhou et al., "Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese," Journal of Cancer Research and Clinical Oncology, vol. 141, no. 9, pp. 1533-1544, 2015.
28. Z. Mojtahedi, M. Mohmedi, S. Rahimifar, N. Erfani, S. V. Hosseini, and A. Ghaderi, "Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer," Gene, vol. 508, no. 2, pp. 229-232, 2012.
29. D. Hua, J. Sun, Y. Mao, L.-J. Chen, Y.-Y. Wu, and X.-G. Zhang, "B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma," World Journal of Gastroenterology, vol. 18, no. 9, pp. 971-978, 2012.
30. Y. Arai, H. Saito, and M. Ikeguchi, "Upregulation of TIM-3 and PD-1 on CD4+ and CD8+ T cells associated with dysfunction of cell-mediated immunity after colorectal cancer operation," Yonago Acta Medica, vol. 55, no. 1, pp. 1-9, 2012.
31. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer," The New England Journal of Medicine, vol. 366, no. 26, pp. 2443-2454, 2012.
32. J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow et al., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer,"The New England Journal of Medicine, vol. 366, no. 26, pp. 2455-2465, 2012.
33. R. A. Droeser, C. Hirt, C. T. Viehl et al., "Clinical impact of programmed cell death ligand 1 expression in colorectal cancer," European Journal of Cancer, vol. 49, no. 9, pp. 2233-2242, 2013.
34. K. Heinimann, "Toward a molecular classification of colorectal cancer: the role of microsatellite instability status," Frontiers in Oncology, vol. 3, article 272, 2013.
35. D. T. Le, J. N. Uram,H. Wang et al., "PD-1 blockade in tumors with mismatch-repair deficiency," The New England Journal of Medicine, vol. 372, pp. 2509-2520, 2015.
36. E. J. Lipson,W. H. Sharfman,C.G. Drake et al., "Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody," Clinical Cancer Research, vol. 19, no. 2, pp. 462-468, 2013.
37. G. Betts, E. Jones, S. Junaid et al., "Suppression of tumourspecific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer," Gut, vol. 61, no. 8, pp. 1163-1171, 2012.
38. Y. Wang, X. Wang, and R. Zhao, "The association of CTLA-4 A49G polymorphism with colorectal cancer risk in a Chinese Han population," International Journal of Immunogenetics, vol. 42, no. 2, pp. 93-99, 2015.
39. L. Wang, F. Jing, D. Su et al., "Association between CTLA-4 rs231775 polymorphism and risk of colorectal cancer: a meta analysis," International Journal of Clinical and Experimental Medicine, vol. 8, no. 1, pp. 650-657, 2015.
40. L. He, T. Deng, and H. S. Luo, "Association between cytotoxic T-lymphocyte antigen-4 +49A/G polymorphismand colorectal cancer risk: a meta-analysis," International Journal of Clinical and Experimental Medicine, vol. 8, pp. 3752-3760, 2015.
41. N. J. Llosa, M. Cruise, A. Tam et al., "The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints," Cancer Discovery, vol. 5, no. 1, pp. 43-51, 2015.
42. Y.-C. Lin, J. Mahalingam, J.-M. Chiang et al., "Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer," International Journal of Cancer, vol. 132, no. 6, pp. 1341-1350, 2013.
43. H. Svensson, V. Olofsson, S. Lundin et al., "Accumulation of CCR4+CTLA-4 hiFOXP3 +CD25 hi regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells," PLoS ONE, vol. 7, no. 2,Article ID e30695, 2012.
44. M. Scurr, K. Ladell, M. Besneux et al., "Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3 T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells," Mucosal Immunology, vol. 7, no. 2, pp. 428-439, 2014.
45. K. Y. Chung, I. Gore, L. Fong et al., "Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer," Journal of Clinical Oncology, vol. 28, no. 21, pp. 3485-3490, 2010.
46. C. Zhu, A. C. Anderson, A. Schubart et al., "The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity," Nature Immunology, vol. 6, no. 12, pp. 1245-1252, 2005.
47. B. Xu, L. Yuan,Q. Gao et al., "Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer," Oncotarget, vol. 6, no. 24, pp. 20592-20603, 2015.
48. D. S. Shin and A. Ribas, "The evolution of checkpoint blockade as a cancer therapy: what's here, what's next" Current Opinion in Immunology, vol. 33, pp. 23-35, 2015.
49. M. V. Goldberg and C. G. Drake, "LAG-3 in cancer immunotherapy," Current topics in microbiology and immunology, vol. 344, pp. 269-278, 2011.
50. C. Camisaschi, C. Casati, F. Rini et al., "LAG-3 expression defines a subset of CD4+CD25 highFoxp3+ regulatory T cells that are expanded at tumor sites," Journal of Immunology, vol. 184, no. 11, pp. 6545-6551, 2010.
51. N. Gagliani, C. F. Magnani, S. Huber et al., "Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells," Nature Medicine, vol. 19, no. 6, pp. 739-746, 2013.
52. S. D. Blackburn, H. Shin,W. N. Haining et al., "Coregulation of CD8+ T cell exhaustion bymultiple inhibitory receptors during chronic viral infection," Nature Immunology, vol. 10, no. 1, pp. 29-37, 2009.
53. J. Chen and Z. Chen, "The effect of immune microenvironment on the progression and prognosis of colorectal cancer," Medical Oncology, vol. 31, article 82, 2014.
54. J. Denoeud and M. Moser, "Role of CD27/CD70 pathway of activation in immunity and tolerance," Journal of Leukocyte Biology, vol. 89, no. 2, pp. 195-203, 2011.
55. J. Jacobs, V. Deschoolmeester, K. Zwaenepoel et al., "CD70: an emerging target in cancer immunotherapy," Pharmacology & Therapeutics, 2015.
56. C. Claus, C. Riether, C. Schrch, M. S. Matter, T. Hilmenyuk, and A. F. Ochsenbein, "CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth," Cancer Research, vol. 72, no. 14, pp. 3664-3676, 2012.
57. J. Jacobs, K. Zwaenepoel, C. Rolfo et al., "Unlocking the potential of CD70 as a novel immunotherapeutic target for nonsmall cell lung cancer," Oncotarget, vol. 6, no. 15, pp. 13462-13475, 2015.
58. M. C. Ryan, H. Kostner, K. A. Gordon et al., "Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75," British Journal of Cancer, vol. 103, no. 5, pp. 676-684, 2010.
59. L. J. Thomas, L.-Z. He, H. Marsh, and T. Keler, "Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity," Oncoimmunology, vol. 3, no. 1, Article ID e27255, 2014.
60. D. A. Schaer, D. Hirschhorn-Cymerman, and J. D. Wolchok, "Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy," Journal for ImmunoTherapy of Cancer, vol. 2, article 7, 2014.
61. M. Dhainaut, C. Coquerelle, S. Uzureau et al., "Thymus-derived regulatory T cells restrain pro-inflammatory Th1 responses by downregulating CD70 on dendritic cells," The EMBO Journal, vol. 34, no. 10, pp. 1336-1348, 2015.
62. CDX-1127 Program Update, November 2013 at SITC 2013, http://files.shareholder.com/downloads/ABEA-39HH7S/0x0x-704503/ec60d100-ddca-49e3-b42a-4e964f540fcd/SITC%20webcast% 20slides%2011%206%20final.pdf.
63. S. N. Linch, M. J. McNamara, and W. L. Redmond, "OX40 agonists and combination immunotherapy: putting the pedal to the metal," Frontiers in Oncology, vol. 5, article 34, 2015.
64. D. Cepowicz, K. Zareba, M. Gryko, A. Stasiak-Bermuta, and B. Kedra, "Determination of the activity of CD134 (OX-40) and CD137 (4-1BB) adhesive molecules by means of flow cytometry in patients with colorectal cancer metastases to the liver," Polski Przeglad Chirurgiczny, vol. 83, no. 8, pp. 424-429, 2011.
65. J. K. Petty, K. He, C. L. Corless, J. T. Vetto, and A.D. Weinberg, "Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)," The American Journal of Surgery, vol. 183, no. 5, pp. 512-518, 2002.
66. B. D. Curti, M. Kovacsovics-Bankowski, N. Morris et al., "OX40 is a potent immune-stimulating target in late-stage cancer patients," Cancer Research, vol. 73, no. 24, pp. 7189-7198, 2013.
67. A. Pedroza-Gonzalez, C. Verhoef, J. N. M. Ijzermans et al., "Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumorimmunity in patients with primary ormetastatic liver cancer," Hepatology, vol. 57, no. 1, pp. 183-194, 2013.
68. D. A. Schaer, S. Budhu, C. Liu et al., "GITR pathway activation abrogates tumor immune suppression through loss of regulatory T-cell lineage stability," Cancer Immunology Research, vol. 1, no. 5, pp. 320-331, 2013.
69. J. Mitsui, H. Nishikawa, D. Muraoka et al., "Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals," Clinical Cancer Research, vol. 16, no. 10, pp. 2781-2791, 2010
70. J.D. Powderly,M. Gutierrez, D. Wang et al., "Aphase 1b/2, openlabel study to evaluate the safety and tolerability of MEDI6469 in combination with immune therapeutic agents or therapeutic mAbs in patients with selected advanced solid tumors or aggressive B-cell lymphomas," Journal of Clinical Oncology, vol. 33, supplement, abstract TPS3091, 2015, Proceedings of the ASCO Annual Meeting.
71. D. S. Vinay and B. S. Kwon, "4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy," BMB Reports, vol. 47, no. 3, pp. 122-129, 2014.
72. T. Bartkowiak andM. A. Curran, "4-1BB agonists: multi-potent potentiators of tumor immunity," Frontiers in Oncology, vol. 5, article 117, 2015.
73. D. Cepowicz, M. Gryko, K. Zareba, A. Stasiak-Bermuta, and B. Kedra, "Assessment of activity of an adhesion molecule CD134 and CD137 in colorectal cancer patients," Polski Przeglad Chirurgiczny, vol. 83, no. 12, pp. 641-645, 2011.
74. J. Dimberg, A. Hugander, and D. Wagsäter, "Expression of CD137 and CD137 ligand in colorectal cancer patients," Oncology Reports, vol. 15, no. 5, pp. 1197-1200, 2006.
75. H.W. Jung, S. W. Choi, J. I. L. Choi, and B. S. Kwon, "Serum concentrations of soluble 4-1BB, and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis," Experimental and Molecular Medicine, vol. 36, no. 1, pp. 13-22, 2004.
76. S.-H. Chen, K. B. Pham-Nguyen, O. Martinet et al., "Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation," Molecular Therapy, vol. 2, no. 1, pp. 39-46, 2000.
77. G. Mazzolini, O. Murillo, C. Atorrasagasti et al., "Immunotherapy and immunoescape in colorectal cancer," World Journal of Gastroenterology, vol. 13, no. 44, pp. 5822-5831, 2007.
78. M. Sznol, F. Hodi, K. Margolin et al., "Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)," Journal of Clinical Oncology, vol. 26, supplement 15, abstract 3007, 2008, Proceedings of the ASCO Annual Meeting.
79. A. Yonezawa, S. Dutt, C. Chester, J. Kim, and H. E. Kohrt, "Boosting cancer immunotherapy with anti-CD137 antibody therapy," Clinical Cancer Research, vol. 21, no. 14, pp. 3113-3120, 2015.
80. N. H. Segal, A. K. Gopal, B. Shailender et al., "A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer," Journal of Clinical Oncology, vol. 32, no. 5, supplement, abstract 3007, Article ID 05082566, 2014.
81. H. E. Kohrt, A. D. Colevas, R. Houot et al., "Targeting CD137 enhances the efficacy of cetuximab," Journal of Clinical Investigation, vol. 124, no. 6, pp. 2668-2682, 2014.
82. R. Houot and H. Kohrt, "CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies," OncoImmunology, vol. 3, no. 7, Article ID e941740, 2014.
83. R. Elgueta, M. J. Benson, V. C. de Vries, A. Wasiuk, Y. Guo, and R. J. Noelle, "Molecular mechanism and function of CD40/CD40L engagement in the immune system," Immunological Reviews, vol. 229, no. 1, pp. 152-172, 2009.
84. R. J. Barth Jr., D. A. Fisher, P. K. Wallace et al., "A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival," Clinical Cancer Research, vol. 16, no. 22, pp. 5548-5556, 2010.
85. J. Honeychurch, E. J. Cheadle, S. J. Dovedi, and T. M. Illidge, "Immuno-regulatory antibodies for the treatment of cancer," Expert Opinion on BiologicalTherapy, vol. 15, no. 6, pp. 787-801, 2015.
86. A. J. Baxendale, C.W. Dawson, S. E. Stewart et al., "Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth," Oncogene, vol. 24,no. 53,pp. 7913-7923, 2005.
87. N.T. Georgopoulos, A. Merrick, N. Scott, P. J. Selby, A. Melcher, and L. K. Trejdosiewicz, "CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing," International Journal of Cancer, vol. 121, no. 6, pp. 1373-1381, 2007.
88. N. J. Shaw, N. T. Georgopoulos, J. Southgate, and L. K. Trejdosiewicz, "Effects of loss of p53 and p16 function on life span and survival of human urothelial cells," International Journal of Cancer, vol. 116, no. 4, pp. 634-639, 2005.
89. D.H. Palmer, S. A. Hussain,R. Ganesan et al., "CD40expression in prostate cancer: a potential diagnostic and therapeutic molecule," Oncology Reports, vol. 12, no. 4, pp. 679-682, 2004.
90. M. Kinouchi, K. Miura, T. Mizoi et al., "Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients," Hepato-Gastroenterology, vol. 60, no. 122, pp. 83-88, 2013.
91. R. H. Vonderheide andM. J. Glennie, "Agonistic CD40 antibodies and cancer therapy," Clinical Cancer Research, vol. 19, no. 5, pp. 1035-1043, 2013.
92. R. H. Vonderheide, J. M. Burg, R. Mick et al., "Phase i study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors," Oncoimmunology, vol. 2, no. 1,Article IDe23033, 2013.
93. S. Kakarla, X.-T. Song, and S. Gottschalk, "Cancer-associated fibroblasts as targets for immunotherapy," Immunotherapy, vol. 4, no. 11, pp. 1129-1138, 2012.
94. R. Liu, J. Li, K. Xie et al., "FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer," Cancer Research, vol. 73, no. 19, pp. 5926-5935, 2013.
95. J. Zhang and J. Liu, "Tumor stromaas targets for cancer therapy," Pharmacology and Therapeutics, vol. 137, no. 2, pp. 200-215, 2013.
96. M. R. Nazareth, L. Broderick, M. R. Simpson-Abelson, R. J. Kelleher, S. J. Yokota, and R. B. Bankert, "Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells," The Journal of Immunology, vol. 178, no. 9, pp. 5552-5562, 2007.
97. Y. Zhang, H. J. Cao, B. Graf, H. Meekins, T. J. Smith, and R. P. Phipps, "CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts," The Journal of Immunology, vol. 160, no. 3, pp. 1053-1057, 1998.
98. J. Galon, A. Costes, F. Sanchez-Cabo et al., "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome," Science, vol. 313, no. 5795, pp. 1960-1964, 2006.
99. N. Lal, A. D. Beggs, B. E. Willcox, and G. W. Middleton, "An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy," Oncoimmunology, vol. 4, no. 3,Article ID e976052, 2015.
100. Y. Xiao and G. J. Freeman, "The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy," Cancer Discovery, vol. 5, no. 1, pp. 16-18, 2015.
101. K. M. Ilieva, I. Correa, D. H. Josephs et al., "Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma," Molecular Cancer Therapeutics, vol. 13, no. 12, pp. 2769-2783, 2014.
102. Z. A. Cooper, A. Reuben, R. N. Amaria, and J. A. Wargo, "Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma," Oncoimmunology, vol. 3, no. 9,Article ID e954956, 2014.
103. K. M. Mahoney and M. B. Atkins, "Prognostic and predictive markers for the new immunotherapies," Oncology, vol. 28, supplement 3, pp. 39-48, 2014.
104. S. P. Patel and R. Kurzrock, "PD-L1 expression as a predictive biomarker in cancer immunotherapy,"Molecular CancerTherapeutics, vol. 14, no. 4, pp. 847-856, 2015.
105. J. McLaughlin, "PD-L1 as a predictive biomarker for anti-PD-1/anti-PD-L1 therapies in non-small cell lung cancer," OncoTherapy Network, 2014.
106. H. Patel, G. Polanco-Echeverry, S. Segditsas et al., "Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma," International Journal of Cancer, vol. 121, no. 12, pp. 2668-2673, 2007.